Abstract |
A phase II study of 5-FU tablet for 52 patients with cancer of the uterine cervix was undertaken by a cooperative study group consisting of 13 institutions. The clinical response rate in 44 evaluable cases was 31.8% (CR: 3 cases, PR: 11 cases, MR: 2 cases, NC: 19 cases and PD: 9 cases). Efficacy rates of 5-FU tablet according to lesion sites were 44.4% in the uterine cervix, 42.9% in the vaginal wall and cut vaginal end, 25.0% in the lymph nodes and 16.7% in the lung. Histologically, the effectiveness rate was 26.9% for large-cell, non-keratinizing-type- carcinoma, 42.9% for small-cell, non-keratinizing-type, and 60.0% for the keratinizing-type of squamous cell carcinoma. One of three adenocarcinoma cases (33.3%) showed improvement. Some adverse effects were observed in 16 (32.0%) of 50 evaluable cases. A large proportion of the adverse effects were gastro-intestinal disorders, such as nausea, vomiting and anorexia. These results suggested that 5-FU tablet is a useful chemotherapeutic agent against carcinoma of the uterine cervix.
|
Authors | K Sekiba, A Yajima, Y Tenjin, S Kurihara, K Akiya, K Okada, K Noda, M Ozaki, K Hasegawa, T Mori |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 14
Issue 7
Pg. 2365-73
(Jul 1987)
ISSN: 0385-0684 [Print] Japan |
PMID | 3606156
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Carcinoma, Squamous Cell
(drug therapy, surgery)
- Combined Modality Therapy
- Drug Evaluation
- Female
- Fluorouracil
(administration & dosage, therapeutic use)
- Humans
- Middle Aged
- Tablets
- Uterine Cervical Neoplasms
(drug therapy, surgery)
|